Meeting
2018 Genitourinary Cancers Symposium
Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.
Authors
Peter Zang
USC Keck School of Medicine, Los Angeles, CA
Peter Zang , Alexandra Drakaki , Izak Faiena , Betty Chan , Denice Tsao-Wei , Susan G. Groshen , David I. Quinn , Tanya B. Dorff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 422)
DOI
10.1200/JCO.2018.36.6_suppl.422
Abstract #
422
Poster Bd #
F15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Distribution of immune-related adverse events (irAEs) across genitourinary (GU) malignancies.
First Author: Nataliya Mar
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Infections in patients receiving immune checkpoint inhibitors.
First Author: Sutthichai Sae-Tia
First Author: Jeddeo Paul
Poster
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
First Author: Yu Fujiwara